FURTHER ANNOUNCEMENT TO THE EFFECTIVE DISPOSAL OF 3.8% OF PRESMED AUSTRALIA (PTY) LIMITED

Shareholders of Advanced Health (“AVL”) are informed that based on the transaction concluded in terms of the SENS announcement published on 19 June 2018, the mentioned issue of new shares in Presmed Australia (“PMA”) was concluded at a price of AUD 23.37 per PMA share.

After the implementation of this issue of new shares to certain directors of PMA and AVL, AVL retains a shareholding of 90.84% in PMA. The retained holding, valued at a price of AUD 23.37, per share, (R233.47) at an exchange rate of R9,99 per AUD, equates to a total value of AVL’s shareholding in PMA of AUD 16,958 million (R169,414 million).

Shareholders are informed that the original investment in PMA was acquired at a purchase price of AUD13.00 per share, which amounted to R124.67 per share at an exchange rate of R9.59 per AUD, during 2014. The total purchase consideration which amounted to AUD 9.433 million (R90.466 million) was settled by means of the issue of 90.466 million shares of R1.00 each in AVL during the first half of 2014. Based on the above transaction, the present value of AVL’s investment in PMA equates now to R169,414 million. This reflects an increase of 87% in the value of AVL’s investment in Australia.

Since 2014, PMA has acquired 3 stand-alone day surgery facilities, growing its annual total patient throughput from 7,656 patients for the financial year ended June 2014 to 13,751 patients (year to date May 2018), as well as increasing its total facility revenue by 72%. There are currently 127 accredited specialists operating across PMA’s 5 facilities, in Australia. The number of accredited specialists has more than doubled since 2014.

The information in this announcement has not been reviewed and reported on by the Company’s auditors.

Pretoria
3 July 2018

Designated Advisor
Grindrod Bank Limited